Young doctor working

2015 Financial results

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

“We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas.

I’m particularly pleased by the pace of progress in Oncology, with new approvals for both Iressa and Faslodex accompanied by regulatory submissions for AZD9291 and cediranib. The strong performance of the growth platforms and the subsequent upgrade to top-line guidance, together with increased R&D productivity reaffirm the confidence we have in our ability to navigate the final impacts from the loss of exclusivity and meet our revenue targets.”

Teleconference replay

A recording of the analyst presentation and Q&A session will be available until 15:30BST Wednesday 12 August, on the following numbers:

LocationNumberConference ID
UK local 0800 953 1533 75183821#
US (freephone) 1 866 247 4222 75183821#
International +44 1452 55 00 00 75183821#

 

Keeping investors in touch

Download our iPad app now from the app store

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Download and install from the iTunes store